Omrix Biopharmaceuticals, a developer of biosurgical and passive immunotherapy products, registered for an initial public offering Wednesday evening. For the twelve-month period ended September 2005, the NY based company generated nearly $25 million in sales with a gross margin of 21.3%. UBS Investment Bank and CIBC World Markets head the list of underwriters on the deal. Terms and timing have yet to be decided.
